We investigated the effects of long-term benidipine treatment on levels of monocyte and endothelial cell activation markers in hypertensive patients with (n ¼ 28) and without (n ¼ 10) type 2 diabetes mellitus. Benidipine, 4 mg/day, was administered for 6 months; there were no other changes in any of the patients pharmacologic regimens during benidipine treatment. Clinical and biochemical data obtained before and after benidipine administration were compared; all markers were measured by ELISA. The levels of platelet activation markers (CD62P, CD63, and PAC-1), microparticles (monocytederived microparticles: MDMPs, and endothelial cellderived microparticles: EDMPs), chemokines (monocyte chemotactic peptide 1: MCP-1, regulated on activation normally T-cell expressed and secreted: RANTES) and soluble adhesion markers (soluble E-selectin and soluble ICAM-1) differed in the control and hypertension groups. In addition, levels of platelet, monocyte, and endothelial cell activation markers, microparticles, chemokines, and soluble adhesion molecules were higher in hypertensive patients than in those without type 2 diabetes. Furthermore, benidipine administration decreased the concentrations of all these markers. The effect of this drug was significant in diabetes patients with high levels of antioxidized low-density lipoprotein (LDL) antibody. These results suggest that benidipine is effective for the treatment of oxLDL-dependent vascular disorders in hypertensive patients with type 2 diabetes.
Introduction
Type 2 diabetes mellitus increases the risk of cardiovascular disease, 1, 2 and recently, blood pressure as well as glycaemic control has been shown to be important in the management of these individuals. 3 Diabetes mellitus leads to the development of premature atherosclerosis, 4, 5 and atherosclerosis associated with diabetes accelerates diabetic macroangiopathy. 6, 7 Monocytes can synthesize procoagulants, which are largely tissue factors, [8] [9] [10] and monocyte vesiculation is one possible mechanism for the dissemination of membrane-associated procoagulant activities. 11 We recently reported that a high level of monocytederived microparticles (MDMPs) might be a marker for vasculopathies in diabetic patients. 12 Endothelial cells also release microparticles (EDMPs) within minutes of exposure to complement C5b-9. 13 More recently, EDMPs from endothelial cells exposed to tumour necrosis factor a were found to express tissue factor, in addition to constitutive antigens CD31 and CD51, and exhibit functional procoagulant activity.
14 Monocyte chemotactic peptide 1 (MCP-1) is a C-C chemokine for monocytes, 15, 16 and it was recently reported that MCP-1 might contribute to glomerular monocyte infiltration in diabetic nephropathy. 17 Another member of the C-C chemokine family, regulated on activation normally T-cell expressed and secreted (RANTES), 18 is a potent chemoattractant for memory T lymphocytes, monocytes, eosinophils, and basophils. RANTES might also activate specific effector cell populations of these cells. 18, 19 Recently, we reported a correlation between levels of P-selectin-positive platelets and chemokines. 20 In addition to the hypercoagulability resulting from monocyte and endothelial cell activation, diabetic patients also show platelet hyperaggregability with increased levels of platelet activation-markers such as P-selectin. 21 Dihydropyridine Ca channel blockers were recently reported to protect the endothelial function of renal resistance arteries in hypertensive rats 22 and mesenteric arteries in circulatory shock rats. 23 In addition, amlodipine increases NO production in coronary arterial endothelial cells via bradykinindependent mechanisms. 24 On the other hand, Kitakaze et al 25 previously reported that another long-acting Ca channel blocker, benidipine, has the potential to increase cardiac NO levels in ischaemic hearts. Thus, it is possible to use Ca channel blockers to improve the vascular dysfunction involving monocytes and endothelial cells in hypertensive patients with diabetes. However, the effects of long-term treatment with Ca channel blocker on vascular complications in hypertensive patients with type 2 diabetes remains unclear. In the present study, we investigated the effects of long-term treatment with benidipine on the levels of platelet, monocyte and endothelial cell activation markers in hypertensive patients with type 2 diabetes mellitus.
Materials and methods

Patients
The study group included 22 normotensive controls and 38 hypertensive patients. Controls were recruited from our hospital staff and other sources. The protocol regarding this study was approved by the Institutional Review Board of the Medical Institution, and written informed approval was received from each study subject prior to starting the trial in accordance with the guidelines for Good Clinical Practice. Hypertensive patients admitted to our hospital between May 2002 and April 2003 for assessment of their hypertension were recruited. None had inflammatory, coronary artery, or cerebrovascular disease within the previous 3 months or clinically detectable renal, hepatic, infectious, or malignant disease. Antithrombotic agents, including aspirin, were withheld for the duration of the study. In all, 28 of the hypertensive patients had type 2 diabetes and 10 did not. The criteria for the diagnosis of hypertension were a recumbent systolic blood pressure of 4150 mmHg and a recumbent diastolic pressure of 490 mmHg on two or more occasions. 26 Type 2 diabetes was defined according to the American Diabetes Association Criteria. Table 1 shows the clinical characteristics of the hypertensive and control subjects.
Study design
We administered benidipine (Kyowa Hakko Kogyo Co., Tokyo, Japan), 4 mg/day, to the hypertensive patients for 6 months. There were no other changes in any of the patients pharmacologic regimens during benidipine treatment. Clinical and biochemical data obtained before and after benidipine administration were compared.
Flow cytometry of activated platelets
Activated platelets were detected using a modification of a previously reported method. 20, 28 An aliquot (10 ml) of platelet suspension (3 Â 10 8 /ml) was added to 100 ml of Hepes-Tyrode's buffer containing 5 mmol/l EGTA. Platelets (10 ml, 3 Â 10 8 /ml) were then added to the supernatant, and incubation with a fluorescein isothiocyanate (FITC)-labelled monoclonal antibody directed against platelet activation marker was performed for 30 min in the dark at room temperature. After incubation, samples were diluted 1:10 with Hepes-Tyrode's buffer containing 5 mmol/l EGTA, and analysed with an Ortho Cytoron Absolute Analyzer (Ortho Diagnostic Systems, Tokyo, Japan). The instrument was calibrated for fluorescence and side scatter using 1.0 and 2.0-mm beads. For forward and side scatter, the gating area was set so as only to include platelets, while excluding platelet aggregates, debris, and machine noise. The negative line was set using the platelets incubated with fluorescein-labelled mouse IgG. As an index of platelet activation, CD62P expression was quantified by immunostaining with anti-CD62P monoclonal antibody, CLB-thromb/6, (Immunotech, Marseille, France), CD63 (Immunotech), and PAC-1 (Becton Dickinson, CA, USA); these antibodies were used for three different antigens.
Assessment of MDMPs and EDMPs
MDMPs 12 and EDMPs 14, 29 were detected using a previously reported method with some modifica- tions. A 10 ml aliquot of washed intact platelets (3 Â 10 8 /ml) was added to plasma, and the mixture was incubated with FITC-labelled Annexin V (FITCAnn V) and phycoerythrin (PE)-labelled CD14 (PE-CD14) for MDMPs or PE-labelled CD51 (a v b 3 ; PE-CD51) for EDMPs for 30 min in the dark at room temperature. Samples were diluted 1:10 with Hepes-Tyrode's buffer containing 5 mmol/l EGTA and analysed with an Ortho Cytoron Absolute Analyzer (Ortho Diagnostics) that was set to detect only particles bound to FITC-Annexin V and PE-CD14 or PE-CD51. This method was designed to only detect procoagulant MDMPs or EDMPs. Finally, MDMPs and EDMPs were calculated for each sample and expressed per ml of whole blood.
Measurement of MCP-1, RANTES, sE-selectin, and sICAM-1
Blood samples from patients and healthy controls were collected into tubes containing sodium citrate or tubes without anticoagulant. Blood was allowed to clot at room temperature for a minimum of 1 h. Serum or citrated plasma was isolated by centrifugation for 20 min at 1000 g at 41C then stored at À301C until analysis. As positive controls in each assay, we used the recombinant products and standard solutions provided with the commercial kits. Levels of serum MCP-1, RANTES, sE-selectin, and sICAM-1 were measured with a monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) kit from BioSource International Inc. according to the manufacturer's instructions.
Measurement of autoantibodies against oxidized low-density lipoprotein (LDL)
Blood samples from patients and healthy controls were collected into tubes without anticoagulant. Blood was allowed to clot at room temperature for a minimum of 1 h then serum was isolated by centrifugation for 20 min at 1000 g at 41C and stored at -301C until analysis. As positive controls, in each assay we used the recombinant products and standard solutions provided with the commercial kits. The ELISA kit specific for antioxidized LDL antibody was obtained from BIODESIGR International, Inc. (Kennebunk, MA, USA).
Statistics
All data are shown as the mean7s.d. Statistical analyses of differences between the two groups were performed with the paired or unpaired t-test. Changes in markers after benidipine treatment were analysed by two-way analysis of variance (ANOVA). P-values less than 0.05 were considered statistically significant.
Results
Levels of platelet activation markers (CD62P, CD63, and PAC-1), microparticles (MDMPs and EDMPs), RANTES, and soluble adhesion markers (sE-selectin and sICAM-1) were significantly lower in the control group than the hypertension group (Table 2) . However, no significant difference was observed in MCP-1 levels. The levels of all markers were also lower in hypertensive patients without than in those with type 2 diabetes, although the systolic and diastolic blood pressure values before benidipine administration were similar in hypertensive patients with and without diabetes ( Table 3 ). The anti-oxLDL antibody levels obtained for the normotensive controls, hypertensive patients without diabetes, and hypertensive patients with diabetes were 4.272.1 (mean7s.d.), 6.373.6, and 16.17 5.5 AcU/ml, respectively (Figure 1) . The anti-oxLDL antibody levels of hypertensive patients with diabetes exhibited a significant increase compared to those of the controls (Po0.01) (Figure 1 ). Both diastolic and systolic blood pressure decreased significantly in patients with diabetes following benidipine administration (Table 4 ). The levels of all Benidipine and diabetic angiopathy S Nomura et al markers in patients with diabetes also decreased significantly after benidipine treatment (Table 4) . Hypertensive patients with diabetes were classified into two groups according to the value of antioxLDL antibody with reference to the mean of the normotensive controls (8.4 AcU/ml) (group A: antioxLDL antibody p8.4, group B: anti-oxLDL antibody 48.4). There were no significant differences between the two groups concerning the blood pressure-lowering effect of benidipine (Table 5) . On the other hand, the time-dependent decrease in all markers before and after benidipine treatment was more significant in group B than group A (Table 5) .
Discussion
The present study added some new informations for vascular complications in hypertensive patients with type 2 diabetes mellitus ( Table 6 ). The development of hypertension in patients with type 2 diabetes increases the risk of renal and cardiovascular disease. 30 Therefore, normalization of hypertension is a key treatment goal for renal protection and possibly cardioprotection in type 2 diabetes patients. 31 In prospective clinical trials, calcium channel blockers were almost as effective as angiotensin-converting enzyme (ACE) inhibitors for ameliorating the deterioration of renal failure. 32 Calcium channel blockers have diverse effects on glomerular renodynamics in spontaneously hypertensive rats. 33 In the present study, benidipine decreased both systolic and diastolic blood pressure in hypertensive patients with and without type 2 diabetes. In addition, concerning the blood pressure-lowering effect of benidipine, there were no significant differences in blood pressure between the highand low-level anti-oxLDL antibody groups. Therefore, the effect of benidipine on monocytes and endothelial cells described above might be independent of the antihypertensive effect. 22, 23, 25, [34] [35] [36] Various factors are involved in diabetic vascular change, one of which is monocyte/macrophage migration. 16, [37] [38] [39] [40] Migration of monocytes into the vascular subendothelium occurs during the inflammatory response and plays a key role in the development of atherosclerosis. 41 Transendothelial monocyte migration is a multifactorial mechanism that initially involves adhesion of circulating monocytes to cytokine-regulated adhesion molecules expressed on the surface of endothelial cells. 42 The adherent monocytes then move through the endothelial cells towards specific chemokines and differentiate into tissue macrophages in the vessel wall. 43 These results suggest that the activation of platelets and/or monocytes are very important for the development of vascular disorder in hypertensive patients with type 2 diabetes. The results of the present study show that levels of platelet, monocyte, and endothelial cell activation markers, microparticles, chemokines, and soluble adhesion molecules are higher in hypertensive patients with than in those without type 2 diabetes, which supports the above idea. In addition, administration of benidipine decreased the concentrations of all these markers.
MDMPs are functionally procoagulant factors as they express surface tissue factor. 11, 12 However, MDMPs might also be markers of monocyte activation. 11 Recently, we reported that the MDMP concentration is particularly high in diabetic patients with nephropathy and suggested that MDMP concentrations might be a marker for nephropathy progression in type 2 diabetes. 12 The ability of benidipine to inhibit MDMP generation provides additional evidence of the antiatherosclerotic action of this drug. 22, 34, 35 The reduction in circulating levels of chemokines and adhesion molecules following benidipine administration provides confirmatory data and is consistent with the observed improvement in endothelial infarction. 22, 23 In particular, it suggests that benidipine is effective for vascular disorders that involve oxLDL, since the effect of this drug was significant in diabetes patients with high levels of anti-oxLDL antibody. It was previously reported that calcium channel blockers could inhibit the oxidation of LDL. [44] [45] [46] Benidipine also has the same action, because the concentration of anti-oxLDL antibody decreased significantly after benidipine treatment in the present study.
Another action of benidipine might be an antiplatelet effect. Recently, the antiplatelet effects of various classes of calcium antagonists including dihydropyridine have been fully established in in vitro experiments, and some studies using ex vivo techniques showed inhibition of platelet function. [47] [48] [49] In the present study, benidipine treatment resulted in significant improvements in platelet activation markers (CD62P, CD63, and PAC-1). The antiplatelet effects of calcium antagonists could include antiatherosclerotic benefits. In addition to the blood pressure-lowering effect, this effect might also be significant when the risk of macroangiopathy by atherosclerosis is considered.
In conclusion, we investigated the effects of longterm treatment with benidipine on levels of monocyte and endothelial cell activation markers in patients with type 2 diabetes mellitus. The levels of platelet, monocyte, and endothelial cell activation markers, microparticles, chemokines, and soluble adhesion molecules were higher in hypertensive patients than in those without type 2 diabetes. Furthermore, administration of benidipine decreased the concentrations of all these markers. The effect of this drug is significant in diabetes patients with high levels of anti-oxLDL antibody. These results suggest that benidipine is effective for the treatment of oxLDL-dependent vascular disorders in hypertensive patients with type 2 diabetes.
